Pacira BioSciences reported a total revenue of $178.0 million for Q2 2024, with net income reaching $18.9 million, or $0.39 per share (diluted). The company is focused on maximizing the benefit of separate EXPAREL reimbursement for outpatient procedures with the implementation of NOPAIN in January 2025.
Total revenues reached $178.0 million.
EXPAREL net product sales were $136.9 million.
Net income was $18.9 million, or $0.39 per share (diluted).
Adjusted EBITDA amounted to $62.1 million.
Pacira is reiterating its full-year 2024 financial guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance